| Literature DB >> 30700325 |
Yingqiu Xie1, Ayan A Nurkesh2, Nazgul Ibragimova2, Zhuldyz Zhanzak2, Aizhan Meyerbekova2, Zhanna Alexeyeva2, Aiya Yesbolatova2, Madina Satayeva2, Aidana Mustafa2, Limara Manarbek2, Aisulu Maipas2, Akerke Altaikyzy2, Zhibek Keneskhanova2, Burkitkan Akbay2, Zhenbang Chen3.
Abstract
BACKGROUND: Some membrane proteins can translocate into the nucleus, defined as nuclear localized membrane proteins (NLMPs), including receptor tyrosine kinases (RTKs). We previously showed that nuclear MET (nMET), a member of RTKs, mediates cancer stem-like cells self-renewal to promote cancer recurrence. However, it is unknown that nMET or mMET, which is the ancestor in the evolution of cancer cell survival and clearance. Here, we aim to study the NLMP functions in cell death, differentiation and survival.Entities:
Keywords: Cancer evolution; Cell death; Drug resistance; MET; Nuclear localized membrane protein (NLMP)
Mesh:
Substances:
Year: 2019 PMID: 30700325 PMCID: PMC6354337 DOI: 10.1186/s13046-018-1004-z
Source DB: PubMed Journal: J Exp Clin Cancer Res ISSN: 0392-9078
Fig. 1Functional analysis of nuclear localized membrane proteins in different biological activities using database. Functions of different nuclear localized membrane proteins were summarized using reported data. Nuclear localized membrane proteins were searched from the literatures of PubMed and google scholar and analyzed with biological functions
Fig. 2Phylogeneticly evolutionary analysis of nMET and nEGFR in different species. Alignment of sequences of nuclear localization signal (NLS) and transmembrane domain (TM) domain of EGFR (a, c) and MET (b, d) were analyzed and mutated sequences were counted and hit. The phylogenetic trees were constructed by methods described in main text using database [19–23]
Fig. 3Nuclear MET associates with DNA damage and p21. a-b Nuclear MET of GFP fusion protein colocalizes with DNA damage and repair marker in HeLa cells upon drug treatment by doxorubicin (DOX). c-d Nuclear MET correlates and colocalizes with p21 in PC3 cells. e-f Nuclear MET associates with p21 in the dead cell or attached cell
Fig. 4Nuclear MET associates with p21 in cell cycle of single cells. a PC3 cells were immunostained with anti-p21, anti-MET antibodies and DAPI. Cell cycle undergoing cells were listed in differential phases. b A proposed summary and model that nMET induced p21 and cell self-clearance may not affect whole cell cycle of population but single cells may evolve via reprograming or be selected as a cancer stem cell for survival
Fig. 5Effect of nuclear MET overexpression on cell cycle, cell death and survival signaling. a-c Effect of nuclear MET elevation on cell cycle by flow cytometry analysis. Cells indicated were transfected by plasmid containing CMV promoter-nMET gene and cell cycles were analyzed by DNA content. d Nuclear MET overexpression induces cell death and survival proteins in HeLa and HEK293 cells by western blot
Fig. 6Nuclear MET mediates stemness and drug resistance. a Nuclear MET expression in PC3 cells upon drug response to doxorubicin (DOX). b Breast cancer MCF7 cells cytotoxicity assay upon treatment with DMSO (control), 60 nM doxorubicin (DOX) alone, antibody (Ab) against MET alone and combined treatment with Dox and antibody against MET. c Nuclear MET induces stem-like cell growth by colony formation assay. d Nuclear MET expression in stem-like cells of C4-2B formed sphere. e C4-2B formed spheres express stem cell markers of SOX2 and OCT4. f-i MET knockdown decreases cancer cell colony formation and membrane MET inhibition by MET antibody (MET Ab) further decreases colony formation
Fig. 7Nuclear receptor tyrosine kinases mediate poor prognosis based on database search and analysis. a The counted hits of reported clinical cohort studies were analyzed and most reported cases suggested the poor prognosis of nuclear localized RTKs compared to membrane RTKs. b A proposed model of nuclear RTK may through nuclear localization to clear unfitted dead cell to maintain membrane MET survival but may allow stem-like cells evolved to advanced recurrent cancer